#USA #New York #Ostro #DTRF #Desmoid Tumors

Ostro Partners with DTRF for Enhanced Patient Support

In a groundbreaking initiative as Rare Disease Month approaches, Ostro has announced its partnership with the Desmoid Tumor Research Foundation (DTRF), aiming to significantly improve access to vital resources for patients and caregivers impacted by desmoid tumors. This collaboration is timely, as it underscores the importance of raising awareness and fostering innovation in rare diseases.

Ostro, a frontrunner in AI-driven digital engagement solutions, is set to integrate its cutting-edge technology pro bono into DTRF's website. This enhancement will facilitate a more user-friendly experience, which is crucial for individuals seeking pertinent information regarding desmoid tumors—an uncommon and often misunderstood condition.

Innovative Technology Meets Patient Needs

Ostro's AI capabilities aim to streamline the process for desmoid tumor community members, guiding them effectively to the most relevant resources. This commitment not only demonstrates Ostro's dedication to applying technology in meaningful ways but also reflects the organization's core mission to transform healthcare engagements and improve outcomes for patients facing complex medical challenges.

Ahmed Elsayyad, the President of Ostro, expressed his enthusiasm for this partnership. He stated, "Our mission is to transform healthcare by delivering innovative, engaging experiences that drive meaningful outcomes to those we serve. Patient associations and foundations, like DTRF, play a pivotal role in the rare disease community, providing essential education and support. We are honored to collaborate with DTRF in support of their invaluable work."

Collaborative Input from Patient Advocates

The collaboration was further enriched by the contributions of several members from DTRF's Patient Advocacy Committee (PAC). Their insights have been critical in refining the platform's user experience, ensuring that it caters to the specific needs of the desmoid tumor community. This cooperative approach has led to the development of a tool that not only simplifies navigation through complex information but also enhances the support structure for patients and caregivers.

Lynne Hernandez, Executive Director of DTRF, emphasized the significance of this partnership: "We are tremendously grateful to the PAC and Ostro for their dedication and expertise in bringing this tool to life. Their contributions have been invaluable in helping us launch a resource that will make a meaningful difference in the lives of those affected by desmoid tumors."

About the Organizations

Ostro specializes in AI-powered digital engagement, focusing on empowering life sciences brands to create significant interactions that result in better outcomes. Through innovative technology, Ostro enables organizations to deliver personalized connections with patients, caregivers, and healthcare providers.

Desmoid Tumor Research Foundation (DTRF) is the only U.S.-based organization dedicated to funding research and finding a cure for desmoid tumors. DTRF actively provides support and education to patients and caregivers and advocates for increased awareness and research initiatives related to this rare disease.

As Rare Disease Month approaches, the partnership between Ostro and DTRF stands as a testament to the power of collaboration and innovation in addressing the challenges faced by individuals with rare diseases. Together, they aim to foster a supportive community where patients and caregivers can access the resources they need to navigate their journeys more effectively.